ArticleOncoimmunology2020

RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic".

Bryan Oronsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.